Prostate Cancer Clinical Trial

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Summary

RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic body radiation therapy and to see how well it works in treating patients with prostate cancer.

View Full Description

Full Description

OBJECTIVES:

Primary

To escalate the dose of stereotactic body radiotherapy (SBRT) to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ-confined prostate cancer. (Phase I)
To determine the late, severe grade 3-5 genitourinary and gastrointestinal toxicity occurring between 270-540 days (i.e., 9-18 months) from the start of the protocol treatment as assessed by CTCAE v3.0. (Phase II)

Secondary

To determine the dose-limiting toxicity of SBRT in these patients. (Phase I)
To determine the 2-year biochemical (PSA) control (freedom from PSA failure), disease-free and overall survival, local control, freedom from distant metastases, and the incidence of high-grade adverse events of any type in patients treated with this therapy in order to determine if the therapy is promising enough for further clinical investigation. (Phase II)

OUTLINE: This is a multicenter, phase I dose-escalation study followed by a phase II open-label study.

Phase I: Patients undergo 5 treatments of stereotactic body radiotherapy (SBRT).
Phase II: Patients undergo SBRT at the maximum tolerated dose as in phase I. After completion of study treatment, patients are followed at 1.5, 3, 6, 9, and 12 months, every 6 months for 5 years, and then once a year for years 5-10.

PROJECTED ACCRUAL: A total of 97 patients will be accrued for this study.

View Eligibility Criteria

Eligibility Criteria

DISEASE CHARACTERISTICS:

Histologically confirmed adenocarcinoma of the prostate

Stage T1a, T1b, T1c disease
Stage T2a or T2b
No direct evidence of regional or distant metastases
No T2c, T3, or T4 tumors
Gleason score ≤ 7

Must meet the following criteria:

Prostate-specific antigen (PSA) ≤ 20 ng/mL prior to starting hormonal therapy (if given) for patients with a Gleason score of 2-6
PSA ≤ 15 ng/mL prior to starting hormonal therapy (if given) for patients with a Gleason score of 7
Risk of pelvic lymph node involvement < 20% according to Roach formula
Ultrasound-based volume estimation of the prostate gland ≤ 60 g

PATIENT CHARACTERISTICS:

Zubrod performance status 0-2
Fertile patients must use effective contraception
No prior invasive malignancy, except for nonmelanoma skin cancer, unless disease-free for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral cavity, or cervix are allowed)

No significant urinary obstructive symptoms

American Urological Association (AUA) score of ≤ 15 (alpha blockers allowed)
No history of inflammatory colitis (including Crohn disease and ulcerative colitis)
No history of significant psychiatric illness

No severe, active comorbidity including any of the following:

Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months
Transmural myocardial infarction within the past 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration

Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects

Laboratory tests for liver function and coagulation parameters are not required for entry into this protocol

AIDS (based on current CDC definition) or other immunocompromising condition

HIV testing is not required for entry into this protocol

PRIOR CONCURRENT THERAPY:

See Disease Characteristics
More than 9 months since prior hormonal therapy as neoadjuvant therapy or to downsize the prostate gland
No prior pelvic radiotherapy
No prior chemotherapy or surgery for prostate cancer
No prior transurethral resection of the prostate (TURP) or cryotherapy to the prostate
No plans for other concurrent post-treatment, adjuvant, antineoplastic therapy including surgery, cryotherapy, conventionally fractionated radiotherapy, hormonal therapy, or chemotherapy as part of the treatment for prostate cancer

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

94

Study ID:

NCT00547339

Recruitment Status:

Completed

Sponsor:

University of Texas Southwestern Medical Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

University of Colorado Cancer Center at UC Health Sciences Center
Aurora Colorado, 80045, United States
MD Anderson Cancer Center Orlando Florida
Orlando Florida, 32806, United States
University of Minnesota Cancer Center at University of Minnesota
Minneapolis Minnesota, 55455, United States
Prairie Lakes Cancer Center
Watertown South Dakota, 57201, United States
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas Texas, 75390, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

94

Study ID:

NCT00547339

Recruitment Status:

Completed

Sponsor:


University of Texas Southwestern Medical Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.